Transcriptomics

Dataset Information

0

Pharmacologic HIF-2α inhibition preserves T cell transcriptome in clear cell renal cell carcinoma


ABSTRACT: Belzutifan is a selective HIF-2α inhibitor currently in clinical trials for clear cell renal cell carcinoma (ccRCC). As belzutifan is being evaluated in combination with immune checkpoint inhibitors, we investigated whether pharmacologic HIF-2α inhibition affects T cell transcriptional programs. Primary human pan T cells isolated from blood from healthy donors and ccRCC patients and tumor-infiltrating T cells were isolated from ccRCC patients. These cells were treated with belzutifan (2 μM, 5 days) vs. control DMSO under hypoxic conditions. RNA sequencing revealed that belzutifan treatment preserved T cell transcriptional programs, supporting the rationale for combining belzutifan with immunotherapy in ccRCC.

ORGANISM(S): Homo sapiens

PROVIDER: GSE324039 | GEO | 2026/04/01

REPOSITORIES: GEO

Dataset's files

Source:
Action DRS
Other
GSE324039_Project_Knm32_2.gene_reads.gct.gz Other
GSE324039_Project_Knm32_2.gene_tpm.gct.gz Other
Items per page:
1 - 3 of 3

Similar Datasets

2026-02-06 | GSE303721 | GEO
2020-07-02 | PXD016630 | Pride
2026-04-01 | GSE324038 | GEO
2023-04-29 | GSE230386 | GEO
2023-06-24 | GSE235292 | GEO
2023-04-01 | GSE221264 | GEO
2026-03-23 | GSE325293 | GEO
2021-04-27 | GSE173363 | GEO
2020-08-21 | GSE156565 | GEO
2013-02-28 | E-GEOD-43416 | biostudies-arrayexpress